Oligonucleotide-based gene therapeutics (OGTs) have emerged as a promising strategy for treating a variety of diseases, offering a tool for gene modulation at the mRNA level.
First-pass extracted concept
oligonucleotide-based gene therapeutics
Candidate: concept label1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
OGTs
Evidence Snippets
Supporting Sources
Linked Claims
Clinically approved oligonucleotide-based gene therapeutics appear to be effective mainly against genetic disorders lacking effective alternative treatment, and their therapeutic contribution remains marginal.
Quoted textsource-backed
Clinically approved OGTs appear to be effective only against genetic disorders that lack effective alternative treatment, and even in these cases their therapeutic contribution remains marginal.
Less than 1% of transfected oligonucleotide-based gene therapeutics are released into the cytosol, limiting interaction with target RNA.
Quoted textsource-backed
Current estimates suggest that less than 1% of transfected OGTs are released into the cytosol, significantly limiting the interaction with target RNA.
The efficacy of oligonucleotide-based gene therapeutics has often fallen short of expectations in experimental and clinical settings.
Quoted textsource-backed
Despite significant progress in OGTs development, their efficacy in both experimental and clinical settings has often fallen short of expectations.